trusight oncology 500 kit (Illumina Inc)
Illumina Inc is a verified supplier 
95
Structured Review
Illumina Inc
trusight oncology 500 kit
Trusight Oncology 500 Kit, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 95/100, based on 108 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trusight/TruSight+Oncology+500+DNA%2FRNA+Kit/pm42791032-61-25-29
Average 95 stars, based on 108 article reviews
Trusight Oncology 500 Kit, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 95/100, based on 108 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trusight/TruSight+Oncology+500+DNA%2FRNA+Kit/pm42791032-61-25-29
Average 95 stars, based on 108 article reviews
trusight oncology 500 kit - by Bioz Stars,
2026-10
95/100 stars
Images
Related Articles
Sequencing:Article Title: Biallelic Variants in the DARS2 Gene as a Novel Cause of Axonal Charcot-Marie-Tooth Disease. Article Snippet: Berta Estévez-Arias, MSc ,1,2,3 Siiri Sarv, MSc ,4 Nathalie Bonello-Palot, PhD ,5,6 Laura Carrera-García, MD,1,7 Carlos Ortez, MD,1,7 Jesica Exp osito-Escudero, MD,1,7 Delia Yubero, PhD,8,9 Jordi Muchart, MD,10 Emilien Delmont, MD,11 Eve Õiglane-Shlik, MD, PhD,4,12 Teele Meren, MD,13 Sanna Puusepp, MD, PhD,14 Ülle Murumets, MD,13 Gajja S. Salomons, PhD,15 Bjarne Udd, MD, PhD,16,17,18 Liis Väli, MD, PhD,4,19 Lara Cantarero, PhD,2,8 Carsten G. Bönnemann, MD ,20 Andrés Nascimento, MD, PhD,1,7,8 Santiago Ram on-Maiques, PhD,8,21,22 Katrin Õunap, MD, PhD,4,13 Janet Hoenicka, PhD ,2,8‡ Daniel Natera-de Benito, MD, PhD ,1,7,8‡ and Francesc Palau, MD, PhD 2,8,23,24‡ Article Title: Biallelic Variants in the DARS2 Gene as a Novel Cause of Axonal Charcot–Marie–Tooth Disease Article Snippet: .. Sequencing was performed with different panels: other:Article Title: AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG). Article Snippet: Lower intensity anti EGFR antibody containing regimens may be suitable for older persons with RAS and BRAF wild type metastatic colorectal cancer.. We found promising activity of 2 such regimens which are worthy of use in selected patients.. Background: Panitumumab (pan) plus chemotherapy is a preferred first-line therapy for unresectable RAS and BRAF wild type metastatic colorectal cancer (mCRC). Article Title: DICER1 in pediatric and adult cancer predisposition populations: prevalence, phenotypes and mosaics. Article Snippet: For the pediatric cohort, library preparation was performed using the TruSight One expanded Article Title: Sanger validation of WGS variants Article Snippet: Arteche-López et al. , Clinical Exome (1109 variants) , Article Title: Long-Read Whole-Genome Sequencing as a Tool for Variant Detection in Inherited Retinal Dystrophies Article Snippet: To test the clinical applications of this technique in IRD cases, we selected a cohort of patients who had previously undergone clinical exome sequencing (CES) using either Clinical Exome Solution (Sophia Genetics, Boston, MA, USA) or TruSight One ( Article Title: Genomic insights into inherited bone marrow failure syndromes in a Korean population. Article Snippet: The TruSight One expanded |